Drugs / SNC115
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06384482 | Apr 2024 → Apr 2025 | lung carcinoma | Shanghai Simnova Biotechnology Co.,Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNC115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06384482 ↗ |
| Modality | Cell therapy | “SNC115 Injection is DLL3 CART.” NCT06384482 ↗ |
| Target | DLL3 | “SNC115 Injection is DLL3 CART.” NCT06384482 ↗ |